key: cord-0834914-awnff2y1
authors: Owen, Allison M.; Fults, Jessica B.; Patil, Naeem K.; Hernandez, Antonio; Bohannon, Julia K.
title: TLR Agonists as Mediators of Trained Immunity: Mechanistic Insight and Immunotherapeutic Potential to Combat Infection
date: 2021-02-18
journal: Front Immunol
DOI: 10.3389/fimmu.2020.622614
sha: 72c368d1d9b866f064626bf2a9b67e854f861970
doc_id: 834914
cord_uid: awnff2y1

Despite advances in critical care medicine, infection remains a significant problem that continues to be complicated with the challenge of antibiotic resistance. Immunocompromised patients are highly susceptible to development of severe infection which often progresses to the life-threatening condition of sepsis. Thus, immunotherapies aimed at boosting host immune defenses are highly attractive strategies to ward off infection and protect patients. Recently there has been mounting evidence that activation of the innate immune system can confer long-term functional reprogramming whereby innate leukocytes mount more robust responses upon secondary exposure to a pathogen for more efficient clearance and host protection, termed trained immunity. Toll-like receptor (TLR) agonists are a class of agents which have been shown to trigger the phenomenon of trained immunity through metabolic reprogramming and epigenetic modifications which drive profound augmentation of antimicrobial functions. Immunomodulatory TLR agonists are also highly beneficial as vaccine adjuvants. This review provides an overview on TLR signaling and our current understanding of TLR agonists which show promise as immunotherapeutic agents for combating infection. A brief discussion on our current understanding of underlying mechanisms is also provided. Although an evolving field, TLR agonists hold strong therapeutic potential as immunomodulators and merit further investigation for clinical translation.

Nosocomial infections, or healthcare associated infections (HCAI), represent a significant cause of global morbidity and mortality, and the United States is no exception. Each year, approximately one out of 25 hospitalized patients in the United States is diagnosed with at least one infection related to hospital care (1) . Infection leading to sepsis remains one of the leading causes of death in U.S. hospitals, affecting more than 1.7 million and causing 270,000 deaths annually. Sepsis is also a major contributor to re-hospitalizations and is one of the most expensive conditions treated in U.S. hospitals, costing more than $2 billion per year (2) (3) (4) . The overall 30-day mortality rate for patients in the intensive care unit (ICU) is approximately 20%, and for patients with sepsis and accompanying organ dysfunction this statistic is 30%-50% (5) . Despite advancements in healthcare overall, this clinical outcome has not improved over the past 25 years (6) .

Critically ill patients are at a significantly increased risk of infection due to injury-or illness-induced immune dysfunction and pathogen exposure through invasive life-saving procedures in the healthcare setting (7) . Further complicating the risk of HCAI is the continuing rise of antibiotic-resistant pathogens. Infections secondary to resistant pathogens are one of the most critical threats to modern medicine, and this situation is being exacerbated by dwindling effective treatment options (8) . The United States has more than 2.8 million antibiotic-resistant infections annually, resulting in more than 35,000 deaths (1) . Solely focusing on the development of new antibiotics is not a permanent solution as pathogens will continue to evolve and become resistant to new drugs (9) . Thus, immunomodulatory therapies that boost host immune responses and protect immunocompromised patients against infections are a highly attractive strategy.

One promising approach to restore immune responses relies on the induction of innate immune memory, also termed trained immunity. Classically, the role of the innate immune system is to recognize a pathogen and mount a broad and rapid response with immunological memory being considered specific to the adaptive immune system. Recent evidence demonstrates that innate immune cells also display long-term adaptive characteristics after initial challenge with pathogens or their products, which results in enhanced capacity to eliminate infections upon subsequent challenge (10, 11) . Trained immunity refers to the phenomenon of activating the innate immune system through exposure to pathogen associated molecular patterns (PAMPs), triggering long-term functional reprogramming by which innate leukocytes mount an enhanced antimicrobial response upon exposure to a secondary microbial pathogen (12) . This protection is broad whereby the host is resistant to an array of pathogens for weeks to months once the altered functional state of innate immune training is initiated. Important to note, the terminology referring to different adaptive programs of innate immunity has evolved with the field. Although used somewhat interchangeably in the literature, a consensus has recently been made to clearly differentiate between the four different adaptive programs: differentiation, priming, tolerance, and training (13) . Trained immunity specifically refers to the phenomenon in which the activation status of innate cells returns to baseline after primary stimulation prior to the secondary stimulation. Nevertheless, this active new field of research is rapidly evolving, an arm of which is aimed at taking advantage of trained immunity as an innovative strategy to combat infection (14) .

Emerging evidence suggests that Toll-like receptor (TLR) agonists are a promising class of immunomodulatory agents that confer long-term protection against subsequent infectious challenge via enhanced innate immunity (15, 16) . TLRs play a crucial role in activation of innate immune responses by recognizing PAMPs which then trigger downstream signaling pathways and ultimately stimulate the production of proinflammatory cytokines and type I interferons. Several TLR agonists are recognized widely for their vaccine adjuvant properties and several are FDA-approved for this use, but their ability to induce trained immunity is becoming more recognized. Here, we review recent progress in our understanding of mechanisms of TLR agonist-mediated trained immunity and its strong potential for clinical translation to protect patients against life-threatening infection.

As the first line of defense against pathogens, the innate immune system utilizes pattern recognition receptors (PRRs) to rapidly detect microbes and deploy antimicrobial responses. TLRs are a well characterized family of PRRs comprised of 10 members in humans (TLR1-TLR10) and 12 members in mice (TLR1-9, TLR11-13) that are expressed in innate immune cells (i.e. dendritic cells, DCs; and macrophages) and non-immune cells (i.e. fibroblasts and epithelial cells) (17) . These receptors are synthesized in the endoplasmic reticulum (ER), processed in the Golgi apparatus, and transported to the plasma membrane or intracellular compartment depending on the localization of the PAMP they recognize (18, 19) . TLRs detect a wide array of PAMPs, including Gram negative and positive bacteria, viruses, flagellin proteins, lipids, nucleic acids, and damage-associated molecular patterns (DAMPs). This is in part accomplished by receptor localization to the cell surface or intracellular compartments (20) . TLRs which recognize nucleic acids are localized to intracellular compartments for decreased risk of contact with "self" nucleic acids whereas cell surface TLRs largely recognize microbial membrane compartments and therefore do not require this protective strategy (21) .

TLRs are composed of a horseshoe-like leucine-rich repeat (LRR) ectodomain which interacts with the respective PAMP or DAMP, a transmembrane helix domain, and a cytoplasmic Toll/ IL-1 receptor (TIR) domain which is involved in activation of downstream signaling (22, 23) . Upon ligand binding, TLRs homo-or hetero-dimerize which dictates recruitment of specific TIR containing adaptor proteins for activation of downstream signaling. TLRs signal either by recruiting the adapter molecule myeloid differentiation primary response differentiation gene 88 (MyD88) or the MyD88-independent Toll/IL-1R (TIR) domain-containing adapter producing interferon-b (TRIF) signaling. Initiation of MyD88-or TRIFdependent signaling activates mitogen-activated protein kinases (MAPKs) and IkB kinases (IKKs) that then activate transcription factors to regulate the expression of pro-inflammatory cytokines and chemokines as well as type I interferons ( Figure 1) . Therefore, these pathways trigger unique antimicrobial defenses to confer protection against diverse pathogens. MyD88-and TRIF-dependent signaling cascades are important to consider in the understanding and application of TLRmediated trained immunity.

Upon ligand binding, all TLRs except TLR3 initiate downstream signaling by recruiting adaptor protein MyD88 either directly (TLR9, TLR11, TLR13, TLR7/TLR8, and TLR2/TLR10) or indirectly via the sorting adaptor TIR domain containing adaptor protein (TIRAP; also termed MyD88-adaptor-like, MAL; TLR4, TLR5, TLR2/TLR1, and TLR2/TLR6) (18, 24) . TIRAP binds with different lipids depending on TLR localization which mediates assembly of kinases (IRAK4 and either IRAK2 or IRAK1) termed the "Myddosome" (17, 25, 26) . Through formation of this oligomeric signaling complex, the kinase domains of IL-1 receptor-associated kinases (IRAKs) are phosphorylated. Activated IRAK1 associates with TRAF6 and the TAK1 protein kinase complex which culminates in activation of the transcription factors nuclear factor-kB (NF-kB) and activator protein-1 (AP-1) via IKKs and MAPK, respectively. Thus, MyD88-dependent TLR signaling results in translocation of NF-kB and AP-1 to the nucleus for production of proinflammatory mediators, playing a critical role in triggering an inflammatory response for defense against an invading pathogen.

Beyond its role in stimulating inflammation, MyD88 is a key regulator of phagocytosis of bacteria by macrophages (27) and DCs (28) via IRAK4 and p38 MAPK (29) which lead to the expression of scavenger receptors. This pathway also influences phagocytosis via NADPH oxidase assembly and thus superoxide production for bacterial killing (30) . Upon TLR4 stimulation by lipopolysaccharide (LPS) in macrophages, it has been found that MyD88 signaling also activates Src tyrosine kinase via the cytoplasmic protein EGF receptor pathway substrate number 9 [Eps8 (31) ] which causes actin cytoskeleton rearrangement. Although alternate MyD88independent pathways have been identified [actin-Cdc42/Rac pathway (32); CD14/complement receptor 3 (33) ], the MyD88 pathway seems to be the main driver of phagocytosis of Borrelia burgdorferi (34) . It also plays a role in phagocytosis of fungal pathogens, although this differs depending on the fungal challenge (35) . The role of MyD88 signaling in innate immunity is highlighted by high incidence of life-threatening infection in patients with MyD88 and IRAK4 deficiencies (36, 37) .

TLR3 exclusively signals through the TRIF-dependent pathway through direct interaction, whereas TLR4 uniquely signals through MyD88 at the cell surface or through TRIF (also referred to as TICAM-1) upon internalization of the receptor complex after ligand binding (20) . Trafficking of TLR4 to the endosomal compartment is dependent on CD14 (38, 39) . After TLR4 endocytosis, the recruitment of the adaptor protein TRAM (also termed TICAM-2) is coordinated with the release of the TIRAP-MyD88 complex (19, 40) . From the endosomal compartment, TLR3 and TLR4 associate with the TRAM-TRIF complex which interact with TNF receptor-associated factor 6 (TRAF6) and lead to activation of NF-kB or AP-1 and downstream production of inflammatory cytokines. Alternatively, interaction with TRAF3 induces interferon regulatory factors 3 (IRF3) or IRF7 and downstream production of type I interferons (17, 40) . Briefly, TRAF6 activates the TAK1 complex that subsequently activates NF-kB and MAPKs via the IKK family member NF-kB essential modifier (NEMO). On the other hand, TRAF3 recruits TBK1 and IKKi resulting in phosphorylation of IRF3 or IRF7 which dimerize and translocate to the nucleus to induce to transcription of IFNs. Additional intricacies of the TRIF-dependent signaling cascade are reviewed by Ullah et al. (18) . Production of type I IFNs is most often associated with defense against double-stranded RNA (dsRNA) viruses; however, they are also important for response to singlestranded RNA (ssRNA) viruses, DNA viruses, and bacteria (41, 42) . TRIF signaling seems to play a role in activation of the adaptive immune system via T cell stimulation. Importantly, TRIF signaling mediates caspase activation, apoptosis, and necroptosis which may play a role in removing infected cells, thus preventing pathogen dissemination via cell death (43) (44) (45) .

Activation of MyD88-dependent and TRIF-dependent signaling cascades allows for immune functional responses specific to the pathogen sensed by TLR ligand binding, as discussed above. Thus, these pathways are subject to several regulatory strategies for the balanced production of inflammatory cytokines and type I IFNs for elimination of pathogens but also to control the magnitude of the response to prevent pathogenic inflammation and autoimmune disease (46) . Such regulatory controls of TLR-mediated inflammatory responses include cooperation with coreceptors, post-translational modifications, cellular trafficking, and negative feedback, which are reviewed in detail by Leifer and Medvedev (47) . Commonly, regulatory molecules (1) interfere with signaling complex formation via TIR domain-containing molecules, (2) prevent association of TRAF6 or TRAF3 with their respective signaling complexes via deubiqutinases (48-50), (3) competitively inhibit downstream signaling (51), or (4) provide mRNA stability of signaling molecules regulated by miRNAs (50) , or cytokines by RNA-binding proteins (52) .

Interestingly, both MyD88-dependent and TRIF-dependent pathways are required for maximal antimicrobial responses upon LPS-activation of TLR4 (53) , demonstrating that they work in concert rather than being redundant. As such, TLR4 signaling is tightly controlled by localization, internalization upon ligand binding (thus acting as a temporal regulator), as well as influence of regulatory molecules. In addition to MAPK and NF-kB pathway activation upon TLR stimulation, the PI3K pathway is also activated via B-cell adaptor for PI3K (BCAP) in FIGURE 1 | TLR signaling pathways mediated through MyD88-or TRIF-dependent cascades. Cell surface Toll-like receptors (TLRs) include TLR4 and TLR5 which form homodimers upon recognition of their classic ligands lipopolysaccharide (LPS) and flagellin, respectively. TLR2 is also localized on the cell surface which heterodimerizes with TLR1 or TLR6, dependent on ligand recognition with either triacyl or diacyl lipopeptides. TLR recognition of PAMPs on common pathogens are indicated. These cell surface TLRs signal via the adaptor protein myeloid differentiation primary response protein (MyD88) through MyD88-adapter-like protein (MAL) also referred to as TIR Domain Containing Adaptor Protein (TIRAP). Intracellular TLRs include TLR9, stimulated by agonist CpG oligodeoxynucleotides (CPG) and the heterodimer TLR7/TLR8, stimulated by single stranded DNA (ssDNA) which signal through direct interaction with MyD88. Activation of MyD88 signaling induces phosphorylation of IL-R-associated kinases (IRAKs) dependent on TLR localization which in turn interacts with TNF receptor-associated factor 6 (TRAF6) and downstream activation of the TAK1 (transforming growth factor b-activated kinase 1)/TAB (TAK1-binding protein) complex. The TAK1/TAB complex activates mitogen-activated protein kinases (MAPKs) or the IkB kinase (IKK) complex of which NF-kB essential modulator (NEMO) is the regulatory subunit. These signaling events activate transcription factors activator protein-1 (AP1) and nuclear factor-kB (NFkB), which translocate into the nucleus for transcription of inflammatory mediators. As a result, pro-inflammatory cytokines and reactive oxygen species drive bacterial killing and limit viral replication as well as stimulate leukocyte recruitment to clear the infectious pathogen. Alternatively, TLR3 recognizes double stranded DNA (dsDNA) and uniquely signals through the adaptor protein Toll/IL-1R (TIR) domain-containing adapter producing interferon-b (TRIF) which interacts with TRAF3. TLR4 also activates TRIF through endocytosis, which activates TRIF signaling via the sorting adaptor protein TRIF-related adaptor molecule (TRAM). Activated TRAF3 signals through IKKi/IRAK1 or IKKi/TBK1 which activate the transcription factors interferon-regulatory factor (IRF) 7 and IRF3, respectively, which translocate to the nucleus for transcription of type I interferons (IFNs). Type I interferons act to inhibit viral replication as well as stimulate adaptive immunity. TRIF-dependent TLR4 signaling can also activate TRAF6 via receptor interacting protein (RIP)-1 for late NFkB signaling. B-cell adaptor for phosphatidylinositol 3-kinase (PI3K) (BCAP) also seems to be an adaptor protein that confers negative feedback on NFkB-mediated inflammation via PI3K as a regulatory mechanism. macrophages (54, 55) and DCs (56) . BCAP/PI3K signaling serves as a negative feedback arm which limits NF-kB induced inflammation and acts as an endogenous regulatory mechanism (57) . Additionally, the adaptor TRAF3 has been found to play an inhibitory role on TLR-mediated MAPK activity through preventing the release of the TAK1 signaling complex (58, 59) , while peroxiredoxin-1 (PRDX1) attenuates NF-kB activation via attenuation of ubiquitin-ligase activity of TRAF6 (60) . Understanding these endogenous negative feedback mechanisms will be highly useful while translating TLRmediated trained immunity for clinical application to protect patients against infection with careful attention as to limit inflammatory responses.

Innate Immune Cell Types Which Drive Toll-Like Receptor-Induced Trained Immunity TLR agonists have exhibited highly attractive immunomodulatory properties whereby they induce augmentation of cell recruitment, antimicrobial effector functions (i.e. phagocytosis, respiratory burst, production of proinflammatory cytokines and chemokines), bacterial clearance, attenuate inflammation, and trigger cross-protection to infection with clinically relevant pathogens (61) . Importantly, trained immunity is not dependent on T and B lymphocytes as evidenced by preserved protection against several models of infection in transgenic RAG2 knockout mice comparative to survival benefit observed in wild type animals (62, 63) .

To date, TLR-mediated innate immune cellular responses have largely been studied in monocytes, macrophages, and natural killer (NK) cells which show long-term functional reprogramming with increased responses to secondary stimulation by bacterial, parasitic, or viral microbes (12, 62, 64) ( Figure 2 ). As the 'first responders' to infection, neutrophils play a key role in TLR-mediated resistance to infection via increased recruitment and function (65) (66) (67) . Similarly, activation of macrophages by TLR signaling results in increased antimicrobial effector functions (phagocytic capacity, respiratory burst, altered production of inflammatory mediators) (63) . Importantly, both neutrophils and macrophages are required for TLR4-mediated resistance to infection. DCs can be activated by TLR signaling or secondary to TLR-activation of NK cells which 'bridge the gap' between innate and adaptive immunity whereby activated and matured DCs migrate to the lymph nodes and subsequently activate naïve T-cells (15, 68) . Thus, immunomodulation of DCs by TLR signaling may prove to be an effective vaccine adjuvant strategy (69) . Continued investigation regarding innate immune cell responses to TLRmediated trained immunity will help refine therapeutic strategies to address specific clinical scenarios.

Agonists which stimulate cell surface TLRs 2, 4, and 5 have been widely studied for their potential as immunomodulators and conferring host resistance to infection. Such studies are discussed below and are summarized in Table 1 .

TLR2 recognizes lipid-containing PAMPs of Gram positive bacteria (i.e. lipopeptides, peptidoglycan), as well as viral (i.e. HSV glycoproteins) and fungal (i.e. zymosan) pathogens, and upon activation it forms heterodimers with TLR1, TLR6, or other cell surface molecules such as Dectin-1 and CD36 (86) . Both TLR2/ TLR1 and TLR2/TLR6 result in MyD88-dependent signaling via MAL/TIRAP; however, the TLR2/TLR1 heterodimer is activated by triacyl lipopeptides whereas the TLR2/TLR6 heterodimer is stimulated by diacyl lipopeptides (87) . Several TLR2 agonists have shown promising immunomodulatory effects.

First isolated from Mycoplasma fermentans in 1997 (88), macrophage-activating lipopeptide-2 (MALP-2) has become a well-studied immunomodulator which activates TLR2/TLR6 heterodimer. When administered 24 h prior to challenge with Streptococcus pneumoniae, MALP-2 treatment reduced bacterial load and enhanced leukocyte migration in the lungs (70) . Interestingly, treatment of influenza A virus-infected mice with MALP-2 prior to challenge with S. pneumoniae enhanced leukocyte recruitment and reduced bacterial load in the lungs, and was associated with increased survival and improved body condition (71) . MALP-2 immunomodulation is presumably driven by its ability to rapidly stimulate neutrophil chemotactic activity followed by induction of monocyte chemoattractant protein-1 (MCP-1) activity in the lungs (89) . Further, MALP-2 induces production of proinflammatory cytokines (IL-6, TNF-a) and chemokines (macrophage inflammatory protein-1a and -1b; MIP) (89, 90) . Palma et al. also postulated that the microbicidal effect which they observed of MALP-2 on Mycobacterium tuberculosis was mediated by nitric oxide (NO) production (72) .

As MALP-2 demonstrates attractive immunomodulatory potential, several synthetic analogs of the molecule, termed palmitoylated peptides, have been investigated in the recent decade. The peptide dipalmitoyl-S-glyceryl cysteine (Pam 2 Cys) targets TLR2/TLR1, whereas the peptide tripalmitoyl-S-glyceryl cysteine (Pam 3 Cys) stimulates TLR2/TLR6. These peptides and their derivatives hold strong potential as vaccine adjuvants, with Pam 2 Cys seeming to be more ideal due to increased solubility and potency compared to Pam 3 Cys (91, 92) . A body of evidence suggests that immunostimulation with Pam 2 Cys provides immediate protection against acute infection with influenza virus but also allows for the development of specific immune responses for long-term protection (73) . Such protection is mediated via activation of DCs, increased leukocyte recruitment, and increased production of inflammatory cytokines (73) . Mifsud and colleagues demonstrated that a derivative of Pam 2 Cys mediates potent anti-viral activity against influenza infection but also protects against secondary infections with S. pneumoniae by reducing bacterial burden and inflammation (93) . Although these compounds display promise, their synthesis is expensive; thus, recently a novel inexpensive synthesis strategy of an N-acetylated Pam 2 Cys analog has been developed, which seems to maintain high potency (94) . The potential application of another TLR2/TLR6 agonist, GSK3277329, was studied in the context of chemotherapyinduced neutropenia which demonstrated that repeated daily injections of the compound for 2 weeks effectively restored neutrophil loss in monkeys given chemotherapy treatment (95) . This evidence further illustrates the potential application of TLR agonists in the context of protecting immunocompromised patients from potentially life-threatening infection by boosting innate immunity.

TLR4 recognizes lipopolysaccharide (LPS) and uniquely signals through both MyD88-and TRIF-dependent pathways. Discovered in 1956 by Landy and Pillemer, mice treated with LPS were resistant to subsequent challenge with Gram negative pathogens (74) . Following this work, it became evident that LPS conferred resistance to a broad array of microbes beyond Gram negative bacteria (75, 96) to include Gram positive FIGURE 2 | Potential mechanisms by which TLR agonists trigger trained immunity and host resistance to infection. The stimulation of TLR signaling induces metabolic reprogramming (including alterations in glycolysis, TCA cycle, and oxidative phosphorylation, i.e. OXPHOS) and epigenetic modifications (histone acetylation, methylation, and lactylation) which rewire innate leukocytes for more robust antimicrobial functions upon a secondary infectious challenge. Adaptations of innate cell programs thereby allow for more efficient clearance of pathogens and thus protection against a broad array of infections. Staphylococcus aureus (61) and fungal pathogens (97) as well as polymicrobial sepsis (98) . LPS-mediated resistance to infection is associated with reduced bacterial burden (75, 99) , increased leukocyte recruitment (61, 100) , and attenuated inflammation (101) .

Despite several studies demonstrating its potential therapeutic benefi t, the application of LPS as an immunomodulator for translation to the clinical scenario was largely abandoned due to its toxicity (16, 102) . More recently, derivatives of LPS as well as synthetic molecules have demonstrated potent induction of trained immunity with significantly reduced toxicity, thus holding strong therapeutic potential. Notably, monophosphoryl lipid A (MPLA) is structurally identical to LPS with the exception of the cleaved C1 phosphate group from lipid A which reduces its toxicity 100fold (103, 104) . Binding of MPLA by TLR4 induces both MyD88and TRIF-dependent signaling, although MyD88 signaling seems to be predominant (105) . Similarly to protection conferred by LPS immunomodulation, administration of MPLA prior to infectious challenge provides a survival benefit to an array of pathogens including Gram negative P. aeruginosa, Gram positive S. aureus, viral influenza, and fungal C. albicans (63, 65, 106) . Importantly, MPLA also protects burn-injured mice from wound infection with the clinically relevant pathogen P. aeruginosa (67) and in large animals (sheep (107) demonstrating its capacity to induce protection in the immunocompromised host. MPLAdriven survival benefit lasts for at least 10 days following administration (76) . Evidence suggests that B and T cells are not required for MPLA-mediated protection to S. aureus, neither were recruited monocytes; conversely, depletion of macrophages or neutrophils resulted in loss of MPLA-induced survival benefit (63) . MPLA treatment enhances leukocyte recruitment, bacterial clearance, antimicrobial functions, and attenuates inflammation which all likely play a role in resistance to infection (65, 67) . It is important to highlight that MPLA similarly enhances human neutrophil responses characterized by increased chemotaxis and bacterial killing (108) . Additionally, MPLA stimulates the adaptive immune response whereby it increases antibody titers up to 20-fold (109) and thus is used as an adjuvant in malaria (AS01), human papillomavirus (HPV), and hepatitis B (AS04) vaccines (110, 111) .

With their immunostimulatory properties, it is unsurprising that several synthetic TLR4 agonists have been developed with the goal of clinical translation. One promising class of synthetic TLR4 agonists are phosphorylated hexa-acyl disaccharides (PHADs) which are similar in structure to MPLA as they have only one phosphate group (16) . PHADs similarly bind TLR4 and activate both MyD88-and TRIF-dependent signaling. Hernandez and colleagues recently showed that treating mice with PHADs confers protection to P. aeruginosa and S. aureus, both of which are of high clinical relevance (77) . They found the survival benefit to be associated with increased bacterial clearance, an effect which was observed up to 10 days after treatment. Further, treatment with PHADs increased leukocyte recruitment and antimicrobial functions while attenuating systemic and local levels of proinflammatory cytokines (77) .

Another synthetic lipid A TLR4 agonist, aminoalkyl glucosamine 4-phosphate (AGP), was first found to possess immunostimulatory properties two decades ago (112) . Initially studied for their potential as a vaccine adjuvant (80) , later studies demonstrated that AGPs confer protection to an otherwise lethal influenza challenge as well as to Listeria monocytogenes infection which were associated with increased bacterial clearance (78) . Intranasal administration of AGP either before or after infection with the Gram-negative pathogen Francisella tularensis resulted in increased survival, and interestingly the survivors were protected against rechallenge with aerosolized Francisella novicida (113) . Likewise, intranasal administration of AGPs prior to challenge with Yersinia pestis also extended time to death which was correlated with cytokine production and decreased bacterial load in the lung (80) . Evidence suggests that TLR4 signaling via activation by AGPs induces NF-kB and IRF-3 signaling independent of the co-receptor CD14 (114) .

Additionally, outer membrane vesicles (OMVs) with low endotoxicity by modification of lipid A of LPS (fmOMV) may increase protective benefit of intranasally administered influenza vaccine (115) . Further, fmOMV confers protection against a lethal dose of pandemic viruses (H1N1, PR8, H5N2, and highly pathogenic H5N1) which is dependent on macrophages but independent of neutrophils. Treatment with fmOMV increased macrophage recruitment and production of type I IFNs without observance of adverse effects (81) .

Beyond lipid A compounds, other natural and synthetic TLR4 ligands have been investigated. Fimbriae H protein (FimH) is the receptor-recognizing element of the adhesive organelle type 1 fimbriae on uropathogenic E. coli (UPEC) (116). Mice which receive FimH intranasally are resistant to influenza infection through increased recruitment of neutrophils and production of proinflammatory cytokines (TNF-a and IL-12) and chemokines (RANTES) in a macrophage-independent manner (82) . Fusion of fimH with the MR/P fimbriae protein MrpH from P. mirabilis (MrpH.FimH fusion protein) conferred higher protection to UPEC and P. mirabilis, associated with reduced bacterial burden in the bladder and kidney as well as increased neutrophil recruitment (83) .

Two classes of synthetic small molecule agonists have been studied with modest therapeutic potential. Neoseptin-3 is a more potent TLR4 agonist than LPS despite being structurally unique (117, 118) . Neoseptin-3-activation of TLR4 signaling results in MyD88-and TRIF-dependent signaling and downstream activation of NF-kB and IFN-b but not IFN-a (118) . Evidence suggests that Neoseptin-3 may hold strong vaccine adjuvant properties whereby mice immunized by ovalbumin (OVA) together with the compound had increased OVA-specific IgG production 21 days later when compared to immunized vehicle controls mice. However, these compounds failed to induce TLR4 signaling in human THP-1 monocytes, thus calling into question their therapeutic potential (118) .

TLR5 recognizes bacterial flagellin (119) and signals through MyD88, culminating in the production of inflammatory mediators. Studies have shown that bacterial flagellin is indeed an immunomodulatory agent. Mucosal administration of flagellin conferred resistance to S. pneumoniae lung infection whereby flagellin treatment increased bacterial clearance which was associated with increased neutrophil mobilization independent of B-and T-cells (120) . More recently, this research group showed that sublingual administration of flagellin also effectively protects against pneumonia (85) . Demonstrating cross-protection, treatment with bacterial flagellin was able to prevent infection with or cure ongoing infection of rotavirus in mice independent of adaptive immunity (84) .

Bacterial flagellin also restores antibiotic-impaired innate immunity (121) and improves efficacy of antibiotics in the treatment of influenza virus or pneumonia (122) . Thus, bacterial flagellin may be highly useful in prevention of infection in immunocompetent and immunocompromised individuals, as well as a strategy to combat antibiotic resistant microbes and boost efficacy of current antibiotic drugs.

Numerous TLR agonists which activate intracellular TLRs have also been widely studied for their potential application as immunomodulators that trigger trained immunity, which are summarized in Table 2 .

TLR3 is localized to the intracellular compartment and recognizes viral dsRNA, including that produced during replication of ssRNA viruses or self-RNAs released from damaged cells (86, 143) . Stimulation of TLR3 results in direct interaction with TRIF for downstream activation of IRF3 and modest activation of NF-kB (144) . TLR3/TRIF activation culminates in production of type I IFNs and inflammatory cytokines for killing of invading viruses and has also been found to be important in cross-priming CD8+ T cell responses in a virus-specific manner (21, 145) . As TLR3 signaling is MyD88-independent, the safety and immunostimulatory properties of TLR3-specific agonists is unique among other TLR immunomodulators (146) .

The TLR3-activating synthetic dsRNA molecule polyinosinic:poly-cytidylic acid (poly I:C) was first discovered to confer protection against subsequent viral challenge in 1969 (147) . More recently, it was found that intraperitoneal administration of poly I:C 3 days prior to challenge with E. coli K1 meningitis in neutropenic mice resulted in increased recruitment of NK cells, production of RANTES and IFN-g, and decreased bacterial burden (126) . Pre-treatment with poly I: C resulted in survival benefit of neutropenic but not immunocompetent mice. In another model of infection, poly I: C conferred anti-viral properties (148) which lead to neuroprotection in a mouse model of HSV-1 encephalitis (124) . In a unique oyster model, poly I:C injection protected the organism against subsequent environmental infection by mitigating viral replication which persisted for at least 5 months (148) . It is suggested that the length of the dsRNA dictates distinct antimicrobial functions dependent on cell type which should be considered during study design and data interpretation (149) . It has been posed that the difference in TLR3-mediated protection against viral infection compared to bacterial infection may be due to the production of type I IFNs which impairs bacterial clearance (15) . Indeed, intranasal administration of poly I:C prior to challenge with S. pneumoniae and methicillin-resistant S. aureus increased susceptibility to infection (150) .

Since its creation 5 decades ago, analogs of poly I:C have been rapidly developed in effort to reduce toxicity (146) . The substitution of a uridylic acid at a molar ratio of 12:1 in the synthesis of the poly C strand results in poly I:C 12 U which is more rapidly metabolized in vivo (151) . Pre-treatment with poly I:C 12 U protects against subsequent viral challenge more effectively than poly I:C (123). Interestingly, a protective benefit has also been observed when the molecule was administered 2 days after viral myocarditis infection (152) . In a clinical trial in which poly I:C 12 U was administered to HIV-infected patients, immune function was restored or stabilized (153) ; however, clinical investigation did not progress past phase II clinical trials (154) . Poly I:C 12 U also holds promise as a vaccine adjuvant as it increases efficacy of intranasal H5N1 immunization (155) and intradermal HSV-2 immunization, which conferred resistance to subsequent otherwise lethal HSV-2 infectious challenge (156) . Demonstrating its safety, this compound has been developed as a therapy for chronic fatigue syndrome (157, 158) that is approved in Argentina and has been approved for early access program in the European Union and Turkey, although it does not currently have FDA approval in the United States (Rintatolimod, tradename Ampligen).

Two other chemically stabilized analogs of poly I:C have demonstrated promising immunostimulatory properties. The first being poly IC : LC (termed Hiltonol) which has been shown to protect rhesus monkeys from several viruses including yellow fever, Rift Valley fever, and rabies (159, 160) and has conferred protection against highly viral strains of H4N1 and influenza in mice (161, 162) . Importantly, it was found in 2017 that intranasal administration of poly IC : LC 24 h prior to or 8 h after an otherwise lethal challenge with SARS-CoV conferred survival benefit as well as reduced lung hemorrhage scores and lung viral titers in mice (125) . Additionally, this molecule has been investigated for its potential in boosting immunity of HIV-infected patients which induced transient innate immune responses, suggesting application as a vaccine adjuvant may be appropriate (163) . This line of investigation is being pursued whereby administration of poly IC : LC alongside an antigen stimulates a 'live virus vaccine equivalent' effect whereby antigen-presenting cells (APCs) are activated, T lymphocyte response is elicited, memory T and B cells are generated, and T eff /T reg ratios are increased (164) . Keyhole limpet hemocyanin (KHL) or HPV vaccines elicited significantly elevated antibody responses and Th1 immune responses when administered with poly IC : LC in rhesus Macaques (165) . The second poly I:C stabilized analog is PIKA which has been shown to protect mice against an array of influenza viruses along with decreased viral burden in the lungs and increased recruitment of macrophages, neutrophils, and plasmacytoid DCs (166) . However, application of PIKA has mostly focused on its potential as a vaccine adjuvant for H5N1 (167) (168) (169) , Hepatitis B (HBsAg) (170) , and rabies (171), the latter of which underwent phase II clinical trials with moderate success (172) .

Beyond the poly I:C class of TLR3-stimulating molecules, oral administration of purified L. rhamnosus CRL1505 peptidoglycan confers resistance to RSV infection associated with decreased viral loads in the lungs and augmented cytokine responses (127) . Protection against RSV and subsequent secondary infection to pneumococcal pneumonia was found to be dependent on TLR3 (128, 130) and macrophages (173) . In an immunocompromisedmalnourished model, it was found that immunostimulatory properties of CRL1505 peptidoglycan extended beyond augmentation of innate immunity. Administration of CRL1505 enhanced the Th2 response and recovery of B cells after S. pneumoniae infection (174) . The investigators also found that intranasal administration of CRL1505 prior to challenge with influenza virus was associated with reduced pulmonary injury and viral loads in the lungs via regulation of pro-inflammatory cytokines and increased levels of type I IFNs (129) .

Together, TLR3 agonists hold strong promise, especially in protection against viral infections and for vaccine adjuvant strategies. However, careful attention needs to be paid as to the potential propagation of bacterial infections by TLR3-induced production of type I IFNs.

The endosomally located TLR7 recognizes ssRNA and often plays a role in responding to viral infections through MyD88dependent signaling. The small molecule 1V270 (also designated TMX201) is a TLR7 ligand conjugated with a phospholipid that has been shown to protect mice from an otherwise lethal infection with Bacillus anthracis, Venezuelan equine encephalitis virus, and H1N1 influenza virus (131) . 1V270mediated protection was associated with increased cytokines and chemokines in bronchial alveolar lavage fluids but not in circulation.

The Imidazoquinoline compound Imiquimod is a low molecular weight compound which selectively activates TLR7. Imiquimod is an FDA approved immune response modifier for the topical treatment of genital warts caused by HPV (175) . Imiquimod has also been found to be protective against influenza A infection in mice which was associated with reduced viral replication, airway inflammation, proinflammatory cytokine production, and preservation of body weight (132) . Neonates were also protected against polymicrobial sepsis when infection was initiated 24 h after treatment (66) . It is also important to note that imiquimod may be an effective vaccine adjuvant strategy for influenza (176) .

Additionally, several TLR7 agonists have been shown to improve immunity of hepatitis B-infected hosts and are implicated as potential HBV vaccine adjuvants. When administered together with an alum adjuvant and recombinant hepatitis B surface antigen (HBsAg) protein, the novel TLR7 agonist T7-EA induced HBsAg-specific antibody and restored Tcell responses in a murine model (133) . Similar improvement of HBsAg-specific T-cell function was observed by immunizing HBV-transgenic mice with a TLR7/TLR8 agonist (CL097)conjugated HBV protein (134) . In a prospective clinical study, it was found that oral administration of the TLR agonist GS-9620 increased T-cell responses to HBV peptides demonstrated by increased cytokine production; however, it failed to reduce serum HBsAg levels (135) .

TLR9 is expressed in DCs, monocytes, macrophages, and B cells and recognizes bacterial and viral DNA. Upon ligand binding, it signals through MyD88 directly; however, it is important to note that signaling depends on intracellular localization as a mechanism to fine-tune the immune response. In resting cells, TLR9 is localized to the ER (177) . Recently described in detail by Marongiu et al., trafficking of TLR9 is controlled by the multimembrane protein unc-93 homolog B1 (UNCB1) which is required for the receptor to leave the ER and traffic to the Golgi (178) . After delivery to the plasma membrane, the adaptor protein AP-2 is recruited to mediate internalization of the receptor in a clathrin-dependent mechanism (179) . In parallel to internalization of TLR9, the ligand must also be endocytosed. TLRs are then localized to early endosomal compartments and the pathway bifurcates to either IRF7 signaling endosomes or NF-kB signaling endosomes (180) , which are determined by AP-3 (181) . Thus, the localization of TLR9, presence of co-receptors and co-factors, as well as trafficking of the ligand itself all influence downstream signaling and determine whether proinflammatory cytokines or type I IFNs are produced. Such intricate control also prevents recognition of self-DNA to prevent autoimmune dysfunction.

CpG oligodeoxynucleotides (CpG ODNs) are synthetic molecules which mimic bacterial DNA and stimulate TLR9. Pre-treatment with CpG has been found to protect mice from Leishmania major infection by shifting immune responses from Th2 towards Th1 (136) . CpG conferred survival benefit to Leishmania major and F. tularensis for up to 2 weeks independent of the route of infection (182) . Intrathecal administration of CpG 48 h prior to Klebsiella pneumoniae infection resulted in increased survival, associated with reduced bacterial burden in the lungs and circulation, increased recruitment of neutrophils, NK cells, gd-T cells, and augmented inflammatory response (139) . Interestingly, treatment of methicillin-resistant S. aureus (MRSA)-infected mice with CpG improved survival (142) . Beyond protection against bacterial microbes, CpG conferred survival benefit to viral challenge by HSV-2 which was associated with decreased viral replication (138) via augmentation of the innate immunity (183) . CpG has also conferred protection of neonate mice challenged with Listeria infection (140) as well as neurotropic Tacaribe Arenavirus which was associated with decreased viral load, increased antigen-specific antibodies, and NO production via NO synthase expression (141) . CpG-mediated protection was preserved in T cell-depleted immunocompromised mice (182) . HIV-infected macaques treated with CpG prior to challenge with Leishmania exhibited decreased lesion size and parasite load (137) . The two latter studies clearly demonstrate the clinical potential of CpG to protect immunocompromised populations against opportunistic infections.

In 2017, the FDA approved the use of CpG 1018 as a vaccine adjuvant in a hepatitis B vaccine (Heplisav-B) which has increased efficacy of the vaccine, thus reducing the prior threedose strategy to a two-dose strategy (184) . CpG 1018 increases antibody concentrations, stimulates helper (CD4+) and cytotoxic (CD8+) T cells, boosts T and B cell memory responses, and shifts T cells towards a Th1 response. Researchers have found that the 2-dose HBV vaccine strategy with CpG as the adjuvant compared to the 3-dose strategy with aluminum hydroxide was more effective in patients aged 60-70 years old with type 2 diabetes mellitus (185), a population which typically demonstrates reduced immunogenicity compared to younger and/or non-diabetic populations. Thus, CpG may be a beneficial agent to boost immune responses in vulnerable patient populations.

The Bacillus Calmette-Guerin (BCG) tuberculosis vaccine is the most used vaccine globally which has been demonstrated to confer T cell-independent cross-protection against fungal infection with C. ablicans or with the parasite Schistosomiasis mansoni (186, 187). After adjusting for age and other vaccines, the BCG vaccine is associated with a significantly lower mortality ratio among infants in Ginea-Bissau (188) . In animal studies, BCG-mediated non-specific protection lasts for at least 3 months and is independent of T and B cells (189) and there is evidence that protection may last up to a year (190) . Although the immunization effect of the BCG vaccine against M. tuberculosis requires adaptive immunity, namely T cell activation, the initial response to BCG is through the innate immunity whereby TLR2 and TLR4 and downstream MyD88-dependent signaling are activated (191) . The resulting activation of the NF-kB pathway serves as the link between the innate and adaptive response. Therefore, the BCG vaccine does activate the innate immune response and may be responsible for driving broad protection.

Fungal b-glucans are a promising class of molecules which trigger trained immunity, although the immunostimulatory properties differ depending on the strain from which they were isolated (192) . These naturally derived molecules have been found to confer protection against a model of E. coli peritonitis (193) , S. aureus (194) , influenza (195) , and MRSA (196) and were associated with increased leukocyte recruitment and antimicrobial functions. Treatment of burn-injured mice with glucan phosphate prior to wound infection with P. aeruginosa improved survival, attenuated cytokine production, and decreased bacterial load at the burn wound (197) .

b-glucans bind their specific PRR dectin-1 which results in downstream inflammasome activation. However, b-glucanmediated production of inflammatory cytokines and reactive oxygen species (ROS) is dependent on the cooperation between dectin-1 and TLR2 (198) . Further, TNF-a production in response to zymosan or live fungi is dependent on MyD88 (199) . Thus, b-glucan-mediated trained immunity is dependent on the synergism of dectin-1 and TLR2.

One research group is investigating the potential immunostimulant properties of CL429, which is a novel chimeric compound that was designed to stimulate both TLR2 and NOD2 by covalently linking the NOD2 ligand Murabutide with the TLR2 ligand Pam 2 C (200) . Initially studied as a vaccine adjuvant, they went on to find that CL429 confers protection against pneumovirus (PVM) infection associated with attenuated inflammation (201) and against leptospiral infection for up to 3 months via increased proinflammatory cytokine and chemokine production (202) .

Similar in approach as the CL429 molecule, the TLR9-activating ligand CpG ODN was crosslinked with the dectin-1/TLR2 stimulating agonist b-glucan-Ovalbumin resulting in CpG-OND : AG-OVA dual-targeting nanoparticles as a vaccine adjuvant strategy (203) . Investigators found that the nanoparticles enhanced APC maturation and induced robust Th1 and Th2 responses similar to that triggered by Freund's adjuvant but without the toxicity. Although this novel compound demonstrates promise as a vaccine adjuvant, it would also be of interest to investigate whether it confers broad protection to infection which may be more profound than that mediated by CpG or b-glucan alone, both of which are strong immunomodulators.

As the BCG vaccine seemingly mediates cross-protection against pathogens besides tuberculosis, evidence suggests that some infections also confer cross-protection which is, at least in part, due to trained immunity (10) . For example, administration of an attenuated strain of C. albicans conferred host resistance to subsequent challenge with the Gram-positive bacteria S. aureus; this phenomenon was found to be independent of T cells but was dependent on macrophages (204) . Interestingly, several observations have suggested that viral infections may trigger a similar cross-protection benefit. Barton et al. demonstrated that latent herpesvirus was associated with protection against bacterial L. monocytogenes and against bacterial L. monocytogenes and Y. pestis which was similarly dependent on macrophages (205) . This observation was confirmed by others who elucidated that herpesvirus-induced protection against bacterial infection is transient (approximately 5 months) despite stable viral load (206) . NK cells are also key mediators of cross-protection whereby they expand during the initial infection and are primed to undergo a second expansion as well as produce more cytokines upon a secondary infection (207) . More recently, a Singapore study of military recruits within a 5-year period showed that men infected with influenza were protected against subsequent infection with adenovirus (79) . It should be noted, however, that crossprotection between infections is generally considered to be dependent on both non-specific reprogramming of innate immunity as well as activation of memory T cells.

It is clear that TLR agonists hold strong therapeutic potential to mediate host resistance to subsequent infection; however, this is only one of many potential therapeutic applications of TLR immunomodulators. As TLR signaling cascades culminate in robust inflammation, TLR antagonists are under development for the treatment of chronic infectious and inflammatory diseases (208) . To date, these compounds are generally designed to bind the TLR, thus preventing the binding of agonists responsible for driving inflammation (209) (210) (211) . The TLR4 antagonist Eritoran (E5564) reached Phase III clinical trials for the treatment of sepsis. This synthetic lipid A analogue which prevents LPS from activating TLR4, hypothetically preventing propagation of systemic inflammatory response syndrome (SIRS) characteristic of sepsis. Preclinical and early clinical studies with the compound showed promising anti-inflammatory results in response to LPS (212) (213) (214) , however the study failed to meet its target end-point in phase III (215) . Similarly, another TLR4 antagonist designated Resatorvid (TAK-242) was also studied in the treatment of sepsis and reached Phase III of the clinical trials, however it failed to attenuate inflammation in septic patients (216) .

Recently, the antimalarial drugs chloroquine and hydroxychloroquine have been under investigation for treatment of COVID-19 with the hypothesis that these drugs will prevent glycosylation of the angiotensin-converting-enzyme 2 (ACE2) as well as inhibit endosomal TLR activation (217, 218) . Initial in vitro studies showed potent antiviral activity (219). Randomized trials have not shown improved clinical outcomes in the hydroxychloroquine-treated COVID patients (218, 220, 221) . In another study, the Bruton tyrosine kinase (BTK) inhibitor acalabrutinib was administered to COVID patients for 10-14 days which seemed to improve patient outcomes as indicated by oxygenation (222) .

Although clinical trials using TLR antagonists in the treatment of severe infection have been unsuccessful to date, critical information has been gained from these investigations which provide a strong foundation for future studies. Importantly, this class of compounds is also being widely studied for treatment of chronic inflammatory conditions such as rheumatoid arthritis and autoimmune disorders. One key finding of the clinical trials studying the TLR4 antagonists Eritoran and Resatorvid was that the compounds were welltolerated (215) . Continued drug discovery efforts via high throughput screening and alternative approaches such as targeting the transcriptional regulation of TLRs to suppress their expression rather than direct inhibition of the receptor may move the field forward (223) . These efforts will be also be supported by continued elucidation of TLR signaling mechanisms and immune responses.

Upon inflammatory stimulation, innate leukocytes undergo metabolic reprogramming that is characterized by augmentation of glycolysis and mitochondrial oxidative phosphorylation to meet the increased energy demands for combating an infection (14, 224) . Previous investigations aimed at deciphering the molecular mechanisms of trained immunity-mediated protection against infections have predominantly used the fungal ligand b-glucan (225, 226) . Reviewed in detail by Netea and colleagues, metabolic reprogramming and epigenetic modifications are the key mechanisms of b-glucan-induced trained immunity (226) . It has been shown that Akt/mTOR/HIF-1a signaling is critical in bglucan induced augmentation of glycolysis in monocytes (225) . As opposed to the breadth of mechanistic understanding of trained immunity induced by b-glucan, the molecular mechanisms underlying TLR ligand-induced training of leukocytes are an evolving field. Our studies show that treatment with the TLR4 ligand MPLA not only increases glycolysis but also augments mitochondrial oxidative phosphorylation and mitochondrial biogenesis in concert with increased antimicrobial functions of macrophages (63) . Further, stimulation of macrophages with the classic TLR4 ligand LPS reprograms mitochondrial metabolism leading to increased accumulation of tricarboxylic citric acid (TCA) cycle metabolites that play an important role in TLR agonist-mediated trained immunity (227, 228) .

The finding that a variety of TLR ligands have the ability to mediate protection against infection from a broad array of organisms which activate distinct TLRs, including Grampositive and Gram-negative bacteria, fungi, and viruses, demonstrates that TLR activation has the ability to offer cross-protection against diverse pathogens. Both MyD88 and TRIF activation have been implicated in facilitating signalingdriven metabolic and epigenetic alterations induced by TLR ligands (229) , but little is understood about the roles of these signaling pathways in initiating trained immunity. This raises the question as to whether activation of trained immunity by TLR ligands is mediated through common signaling pathways. Future studies providing insight into these common pathways would pave the way for the discovery of a multitude of potential TLR ligand-based therapeutics to improve resistance to infection. The following sections will provide a succinct overview of leukocyte metabolic reprogramming and epigenetic modifications as the basis for TLR ligand induced trained immunity (Figure 2) . 

Stimulation of macrophages with LPS increases glucose uptake and glycolytic capacity mediated via stabilization and upregulation of hypoxia-inducible factor 1-a (HIF-1a) (230) (231) (232) . Increased glycolytic capacity serves to rapidly generate ATP and provide essential precursors for synthesis of amino acids, lipids, and nucleotides that are necessary for optimal effector activities and cell viability under stress conditions (233) . Our studies have shown that deletion of HIF-1a or inhibition of mammalian target of rapamycin (mTOR; known to stabilize HIF-1a) attenuates MPLA-induced increased glycolysis, abolishing the protective effect of MPLA against infection (63, 76) . Along with augmented glycolysis, reprogramming of mitochondrial metabolism plays a key role in modulating the inflammatory response of innate leukocytes. LPS-induced activation of macrophages introduces 'breaks' in the TCA cycle at the levels of isocitrate dehydrogenase and succinate dehydrogenase (SDH), leading to increased accumulation of citrate and succinate (234) . Studies from our laboratory also show that MPLA treatment cause an early reduction in TCA cycle flux between citrate and aketoglutarate leading to increased accumulation of citrate (63) . Citrate is diverted towards generation of itaconate via increased immunoresponsive gene 1 (Irg1) enzyme expression (235) . Itaconate is being widely investigated for its direct antimicrobial and anti-inflammatory effects. The direct antimicrobial effect of itaconate is mediated via inhibition of the microbial enzyme isocitrate lyase (236) . Itaconate has been shown to inhibit the growth of numerous pathogens including M. tuberculosis, S. aureus, Legionella pneumoniae, Acinetobacter baumanii, and Salmonella enterica (235, 237, 238) . Itaconate can be transported into the phagosome, where it limits microbial growth (239), implying a role for phagolysosomes as a critical site for itaconate's antimicrobial effects. The synthetic itaconate analog, 4-octylitaconate (4OI) exerts anti-inflammatory effects and potently activates the NF-E2-related factor 2 (Nrf2) pathway (240) which regulates the expression of cytoprotective proteins and plays a critical role in redox homeostasis (241) . A study by Swain et al. shows that endogenous itaconic acid fails to activate Nrf2 as compared to 4OI, and that synthetic itaconate analogs do not recapitulate the effects of endogenous itaconic acid (242) . However, endogenous itaconic acid is anti-inflammatory and reduces IL-1b production similar to 4OI (240, 242) . In contrast to these findings, treatment with b-glucan does not induce significant levels of Irg1 and itaconate in human monocytes, and pretreatment with 4OI diminishes b-glucan induced trained phenotype (243) . However, it is important to note that b-glucan focused studies relied on measuring cytokine responses alone as a key for demonstrating the lack of effect of itaconate on b-glucan-induced trained immunity although cytokine responses to an inflammatory stimuli may not correlate with actual protective response (76) .

Beyond the role of citrate in serving as a precursor for itaconate, our studies using MPLA-stimulated macrophages have shown that citrate transported into the cytosol replenishes mitochondrial oxaloacetate pools and fuels a sustained increase in mitochondrial TCA cycle flux (63) . Upon TLR4 stimulation of macrophages, inhibition of SDH activity by itaconate and increased TCA cycle flux also results in succinate accumulation (231, 244) . Increased succinate levels and inhibition of SDH activity stabilize HIF-1a and increase mitochondrial ROS generation which lead to an enhanced inflammatory response (231, 244) . Mitochondrial ROS aid in microbial clearance (245) ; however, this phenomenon requires further investigation. Importantly, MPLA-induced increase in TCA cycle flux is associated with enhanced macrophage antimicrobial effects and protection against infections (63) . Therefore, metabolic reprogramming plays a critical role in TLR ligand induced trained immunity-mediated protection against infections.

Exposure to inflammatory stimulus or pathogens also causes epigenetic reprogramming in innate leukocytes reflected by alterations in the histone acetylation and methylation status (246) . The major histone modifications including acetylation (H3K27ac) and methylation (H3K4me3) in monocytes exposed to b-glucan persist even 7 days after removal of the initial stimulus and are strongly associated with metabolic reprogramming (225) . A study by Saeed et al. showed that LPS and b-glucan induce diverse and opposing alterations in the epigenome with b-glucan showing a greater degree of de novo H3K27ac modifications in gene loci encoding for inflammatory responses (247) . Alternatively, LPS stimulation of human monocytes acutely induces a strong acetylation of H3K27 around Irg1 gene locus within 1 h of stimulation which is associated with increased expression of Irg1 (243) .

Metabolic reprogramming and epigenetic modifications are tightly interconnected. Fumarate accumulates in monocytes stimulated with b-glucan via glutamine anaplerosis. Increased fumarate levels have been shown to downregulate the activity of histone demethylase KDM5 (248) . In turn, decreased KDM5 activity upregulates trimethylation of H3K4 at promoters of genes encoding pro-inflammatory cytokines (248) . aketoglutarate stimulates the jumonji domain containing family of the lysine demethylase enzyme JMJD33. Further, a high aketoglutarate/succinate ratio favors anti-inflammatory phenotype in macrophages (249) .

The post-translational modification of succinylation arising from the addition of succinate to the protein lysine residues supports a pro-inflammatory state in macrophages (231) . Succinylation is known to occur on histone lysine residues in human cells (250) . However, the role of histone succinylation in the context of trained immunity is currently unknown and remains an important question to be addressed in future studies. A study by Zhang et al. showed that lactate can also bind to histone lysine residues (lactylation) and demonstrated 28 distinct histone lactylation sites (251) . This study showed that LPS-induced increase in macrophage lactate levels via increased glycolysis sets in motion a lactylation epigenetic program which directs the expression of genes involved in alternative anti-inflammatory activation state in macrophages (251) . The influence of accumulated metabolites during trained immunity is just beginning to be explored and needs further characterization.

The traditional school of thought is that treatment with TLR ligands such as LPS induces a state of immune tolerance, while leukocytes exposed of b-glucan produce a heightened response to secondary stimulation (trained phenotype) classically reflected by cytokine production (252) . However, as discussed, treatment with clinically applicable TLR agonists protect against a broad array of infections, implying that TLR ligands also induce robust trained immunity. One potential explanation for this discrepancy in the literature regarding whether TLR ligands induce a state of tolerance or training may be due to the reliance on cytokine production upon exposure to a secondary stimuli which has more recently been shown to not be uniformly indicative of antimicrobial immunity (76) . Future studies aimed at detailed characterization of TLR agonist-induced epigenetic reprogramming and defining its link with metabolic reprogramming will be critical in elucidating the mechanisms of TLR agonist-induced trained immunity.

It is important to thoroughly consider that activation of the immune system may have deleterious consequences and requires careful study to identify the clinical situations in which TLR-mediated immunomodulation are most appropriate. Sepsis and septic shock yield a proinflammatory response that results in organ injury; however, survivors demonstrate an immunosuppressive phenotype that results in secondary infections and increased mortality (253, 254) . Likewise, a potentially harmful outcome of TLR agonist treatment is tolerance to subsequent exposure of endotoxin, particularly in the setting of prolonged LPS exposure or treatment, a phenomena also termed as immunoparalysis (255, 256) . Aberrant activation of TLR signaling by PAMPs or DAMPs, mutations of TLR signaling molecules, or failure of self-recognition mechanisms are responsible for development of several diseases such as autoimmune, chronic inflammatory, and allergic diseases (257) . In the field of oncology research, adverse effects from TLR immunotherapy have been linked to unintended expansion of adaptive leukocytes, such in B-cell lymphoma, where activation of TLR4 MyD88-dependent signaling may exacerbate the disease (258) (259) (260) . Other adverse effects of treatment with TLR agonists have been described in cardiovascular medicine research where treatment with oxidized low-density lipoprotein and the BCG vaccine yield a dose-dependent response of proinflammatory cytokines. These mediators damage human coronary smooth muscle cells and increase atherosclerosis which was found to be TLR2-and TLR4-dependent (261) .

Although there are some potential adverse effects of TLR immunotherapy which require consideration, there are several patient populations which may benefit from novel TLR agonist strategies. The oncology patient population presents a challenge due to immunosuppression. Most cancer-associated antigens are selfantigens and require immunostimulant adjuvants in addition to cancer-targeting strategies (262) . In an H22 liver cancer murine model, administration of curdlan sulfate-matured tumor cell lysatepulsed DCs was associated with an increase in CD80, MHC-1 and MHC-II expression, CD8+T cell infiltration, upregulated TNF-a and INF-g transcription, and downregulation of TGF-b transcription in tumor tissues, and improved survival (263) . In a separate study, the use of the TLR3 agonist Ampligen, a GMP-grade synthetic poly I:C derivative, was shown to mature human monocytes derived from DCs and sustained bioactive IL-12 production, and generate Th1 specific anti-cancer responses in peripheral blood T-cells obtained from cancer patients (262) . In a study by Breckpot et al., the zinc finger protein A20 was downregulated in poly I:C treated DCs which led to sustained production of IL-6, IL-10, and IL-12p70, thus making poly I:C a candidate adjuvant for an anti-cancer immunotherapy (264) . Likewise, intratumor administration of the TLR7 agonist 1V270 increased the ratio of M1 to M2 tumor-associated macrophages and was associated with improved survival (265) . In addition to anticancer immunotherapy, TLR agonists have shown promise in reduction of ischemia reperfusion injury in cardiac myocytes (266, 267) . Further, TLR therapy has also been studied in progressive diseases such as Alzheimer's disease, where single or repeated treatment has been shown to reduce evidence of disease progression (268, 269) .

Aside from innate immune cells, non-immune cells are capable of long-term memory, including hematopoietic, mesenchymal, and epithelial stem cells (270) . There is an increasing body of evidence on how the microbiome influences immunity and how probiotic therapy modulates innate immunity (271) . Interestingly, trained immunity may be a mechanism of the beneficial effects of probiotics. Probiotics have been found to augment innate immune function via receptor antagonism or expression, binding or expression of adaptor molecules, expression of regulatory signaling molecules, induction of micro-RNAs, and secretion of immunomodulatory proteins, lipids, and metabolites (271) .

Trained immunity may even play a role in combating the ongoing COVID-19 pandemic. As one of the sequelae of COVID-19 infections include secondary respiratory infections, the BCG vaccine or b-glucan may be adjunct strategies to reduce morbidity and mortality by enhancing immunity (272, 273) . Imiquimod, a TLR7 agonist, has also been proposed as a therapeutic adjunct for COVID-19 and related infections (274) . In summary, there is a growing body of evidence focusing on trained immunity as a mechanism to enhance immunity against a broad array of infections which are common in critically ill patients, but also for several other patient populations as discussed above. Such application requires further investigation to elucidate the full potential of TLR agonist-based immunotherapies ( Table 3) .

Ongoing clinical trials investigating the adjuvant properties of TLR agonists constitute approximately double of those studying them as therapeutics (275) , demonstrating that the immunomodulatory properties of these compounds are largely being harnessed for vaccine development. The application of trained immunity for vaccine development is highly attractive due to its potential to (1) increase nonspecific effector responses of innate immune cells, and (2) to activate DCs to enhance adaptive T cell responses to specific and nonrelated antigens (276) . For example, a novel synthetic small molecule TLR7/8 agonist 3M-052 is now in a phase I clinical trial studying the safety and immunogenicity of the HIV-1 BG505 SOSIP.664 gp140 vaccine candidate (NCT04177355). Other TLR agonists currently in clinical trials as vaccine adjuvant strategies for HIV-1 include TLR3 agonist Poly ICLC (NCT02071095) and TLR9 agonists MGN1703 (NCT02443935) and CpG-7909 (NCT00562939). TLR7 compounds are under investigation as vaccine adjuvant strategies for hepatitis B as well, including Vesatolimod (GS-9620; NCT02166047) and R07020531 (NCT02956850). The TLR9 compound SD-101 is being studied as an adjuvant for chronic hepatitis C (NCT00823862).

On the other hand, the TLR9 agonist Lefitolimod in combination with neutralizing antibodies is in phase II trials studying its effectiveness in conferring reservoir reduction in HIV infection (NCT03837756) after phase I demonstrated its safety and effectiveness in improving both innate and adaptive immunity in HIV-1 infected patients (277) . The TLR7 compound Imiquimod has completed phase II trials for its efficacy in treating human papillomavirus (HPV) when applied topically (NCT00941811).

In addition to the above listed clinical trials regarding investigation of TLR agonists as vaccine adjuvant strategies or drugs to fight infection, numerous TLR ligands are being investigated as immunomodulators to treat chronic inflammatory diseases, cancer, and autoimmune disorders, which can be found listed in Anwar et al. (275) .

Although there are several potential clinical applications of TLR immunomodulators as stand-alone therapies which are supported by a growing body of strong preclinical evidence, several knowledge gaps hinder progress of clinical translation. Much remains to be elucidated regarding duration of protection mediated by TLR agonists, and whether protection could be continued by repeated treatment once protection wanes. Further, the most effective but feasible route of administration is essential to identify, with oral and intranasal administrations likely most practical. Dosing and efficacy for various patient populations is also essential to understand, such as whether aged patients or those with comorbidities respond similarly to healthy young patients. In this regard, one limiting factor remains the use of healthy young animals for the vast majority of preclinical studies which does not recapitulate the clinical situation and therefore limits the amount of information that could be gained prior to starting clinical trials.

Another limiting factor is the striking lack of reporting of clinical trial data; therefore, scientists do not have all of the tools that otherwise could refine ongoing and future studies. Finally, as TLR agonists initiate inflammatory cytokine pathways, one glaring concern remains the potential of these compounds to trigger inflammatory or autoimmune disease. Thus, it is critical to continue elucidating TLR signaling mechanisms to identify potential therapeutic targets which may circumvent this concern in addition to conducting proper dosing studies aimed at avoiding induction of inflammation. Rapid scientific progress has been made since the discovery of the phenomenon of trained immunity and its potential therapeutic application. As the field drives forward to fill in these knowledge gaps, the goal of clinical translation of TLRs as immunomodulators holds strong promise to be realized. 

Unfortunately highlighted during the ongoing SARS-CoV-2 pandemic, immunocompromised patients are highly susceptible to life-threatening infections. Beyond the current healthcare crisis, populations with insufficient immune responses fail to clear pathogens which results in opportunistic infections that are often difficult to combat due to the increasing prevalence of antibiotic resistance. With limited pharmacological tools, it is critical to develop new strategies aimed at combating infection. Here we have reviewed the potential application of TLR agonists as immunotherapies which trigger trained immunity and confer broad protection to microbes. Importantly, since immunomodulation targets the host response rather than the pathogen, development of microbial resistance is unlikely. TLR agonists have also shown promise as adjuvants for cancer-targeting immunotherapies. Moreover, our lab and others have demonstrated that such agonists may be highly useful as standalone therapies to protect against infection through boosting antimicrobial responses of innate leukocytes.

With their instrumental role in stimulating innate immunity and in activation of inflammatory responses, TLRs are tightly controlled by localization to the cell surface or endosomal compartment as well as complex downstream signaling pathways via MyD88-or TRIFdependent cascades. Although much remains to be elucidated, TLRmediated trained immunity seems driven by metabolic reprogramming and epigenetic modifications. It is critical to further elucidate the cell types, signaling pathways, and intracellular mechanisms responsible for conferring the beneficial protective effects of TLR agonists via trained immunity. Doing so will aid the translation of TLR-based immunotherapies to protect patients from potentially life-threatening infections.

The manuscript was conceptualized by AO and JB. AO wrote the sections on TLR signaling pathways, trained immunity triggered by TLR agonists, and drafted the figures. JF wrote the introduction and drafted the tables. NP wrote the sections on metabolic and epigenetic modifications, and AH contributed the section on clinical perspectives. JB supervised the drafting and performed the final editing. All authors contributed to the article and approved the submitted version. 

Antibiotic Resistance Threats in the United States

With special feature on mortality

Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003

Program CDCPE. Incidence and Trends of Sepsis in US Hospitals Using Clinical vs Claims Data

Reducing mortality in sepsis: new directions

National Inpatient Hospital Costs: The Most Expensive Conditions by Payer, 2013: Statistical Brief 204

Noninvasive ventilation for patients near the end of life: what do we know and what do we need to know?

Antimicrobial resistance: global report on surveillance

Antibiotic resistance sweeping developing world

Trained immunity: a memory for innate host defense

Long-term reprogramming of the innate immune system

Trained immunity: A program of innate immune memory in health and disease

Trained immunity, tolerance, priming and differentiation: distinct immunological processes

The Metabolic Basis of Immune Dysfunction Following Sepsis and Trauma

TLR Agonists as Modulators of the Innate Immune Response and Their Potential as Agents Against Infectious Disease

Immunobiology and application of toll-like receptor 4 agonists to augment host resistance to infection

Toll-like receptor signaling pathways

TRIF-dependent TLR signaling, its functions in host defense and inflammation, and its potential as a therapeutic target

Assembly and localization of Toll-like receptor signalling complexes

Below the surface: The inner lives of TLR4 and TLR9

Toll-like receptors and their crosstalk with other innate receptors in infection and immunity

The structural biology of Toll-like receptors

Toll-like receptor signal transduction

The history of Toll-like receptorsredefining innate immunity

Phosphoinositide-mediated adaptor recruitment controls Toll-like receptor signaling

Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling

Toll-like receptors induce a phagocytic gene program through p38

TLR-dependent phagosome tubulation in dendritic cells promotes phagosome cross-talk to optimize MHC-II antigen presentation

Regulation of phagosome maturation by signals from toll-like receptors

Cutting edge: MyD88 controls phagocyte NADPH oxidase function and killing of gram-negative ba cteria

Eps8 protein facilitates phagocytosis by increasing TLR4-MyD88 protein interaction in lipopolysaccharide-stimulated macrophages

MyD88-independent activation of a novel actin-Cdc42/Rac pathway is required for Toll-like receptor-stimulated phagocytosis

CD14 cooperates with complement receptor 3 to mediate MyD88-independent phagocytosis of Borrelia burgdorferi

Distinct roles for MyD88 and Toll-like receptors 2, 5, and 9 in phagocytosis of Borrelia burgdorferi and cytokine induction

Differential role of MyD88 in macrophage-mediated responses to opportunistic fungal pathogens

Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency

Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity

CD14 controls the LPS-induced endocytosis of Toll-like receptor 4

Phospholipase Cgamma-2 and intracellular calcium are required for lipopolysaccharide-induced Toll-like receptor 4 (TLR4) endocytosis and interferon regulatory factor 3 (IRF3) activation

TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta

A unique host defense pathway: TRIF mediates both antiviral and antibacterial immune responses

IL-15 cis presentation is required for optimal NK cell activation in lipopolysaccharidemediated inflammatory conditions

Mechanisms of the TRIFinduced interferon-stimulated response element and NF-kappaB activation and apoptosis pathways

Toll-like receptors activate programmed necrosis in macrophages through a receptor-interacting kinase-3-mediated pathway

Tolllike receptor 3-mediated necrosis via TRIF, RIP3, and MLKL

Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer

Molecular mechanisms of regulation of Toll-like receptor signaling

Direct, noncatalytic mechanism of IKK inhibition by A20

The orphan nuclear receptor SHP acts as a negative regulator in inflammatory signaling triggered by Toll-like receptors

Dissecting negative regulation of Toll-like receptor signaling

A Structural View of Negative Regulation of the Toll-like Receptor-Mediated Inflammatory Pathway

Regulation of mRNA stability by CCCH-type zinc-finger proteins in immune cells

Dual signaling of MyD88 and TRIF is critical for maximal TLR4-induced dendritic cell maturation

Bcell adaptor for PI3K (BCAP) negatively regulates Toll-like receptor signaling through activation of PI3K

Role for B-cell adapter for PI3K (BCAP) as a signaling adapter linking Tolllike receptors (TLRs) to serine/threonine kinases PI3K/Akt

BCAP Regulates Dendritic Cell Maturation Through the Dual-Regulation of NF-kappaB and PI3K/AKT Signaling During Infection

Cross talk of the first-line defense TLRs with PI3K/Akt pathway, in preconditioning therapeutic approach

Deciphering the complexity of Toll-like receptor signaling

Different modes of ubiquitination of the adaptor TRAF3 selectively activate the expression of type I interferons and proinflammatory cytokines

Inhibition of TRAF6 ubiquitin-ligase activity by PRDX1 leads to inhibition of NFKB activation and autophagy activation

Endotoxin pretreatment improves bacterial clearance and decreases mortality in mice challenged with Staphylococcus aureus

Candida albicans infection affords protection against reinfection via functional reprogramming of monocytes

The TLR4 Agonist Monophosphoryl Lipid A Drives Broad Resistance to Infection via Dynamic Reprogramming of Macrophage Metabolism

Neutrophils prime a long-lived effector macrophage phenotype that mediates accelerated helminth expulsion

The Toll-like receptor 4 agonist monophosphoryl lipid a augments innate host resistance to systemic bacterial infection

Defective innate immunity predisposes murine neonates to poor sepsis outcome but is reversed by TLR agonists

Role of G-CSF in monophosphoryl lipid A-mediated augmentation of neutrophil functions after burn injury

Dendritic cells and the control of immunity

Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity

Immunostimulation with macrophage-activating lipopeptide-2 increased survival in murine pneumonia

Pulmonary immunostimulation with MALP-2 in influenza virusinfected mice increases survival after pneumococcal superinfection

The toll-like receptor 2/ 6 ligand MALP-2 reduces the viability of Mycobacterium tuberculosis in murine macrophages

Intranasal administration of the TLR2 agonist Pam2Cys provides rapid protection against influenza in mice

Increased resistance to infection and accompanying alteration in properidin levels following administration of bacterial lipopolysaccharides

Endotoxin priming improves clearance of Pseudomonas aeruginosa in wildtype and interleukin-10 knockout mice

The Cytokine Response to Lipopolysaccharide Does Not Predict the Host Response to Infection

Phosphorylated Hexa-Acyl Disaccharides Augment Host Resistance Against Common Nosocomial Pathogens

Immunostimulatory activity of aminoalkyl glucosaminide 4-phosphates (AGPs): induction of protective innate immune responses by RC-524 and RC-529

Evidence for Cross-Protection Against Subsequent Febrile Respiratory Illness Episodes From Prior Infections by Different Viruses Among Singapore Military Recruits 2009-2014

Induction of innate immunity by lipid A mimetics increases survival from pneumonic plague. Microbiol (Reading)

Bacterial Outer Membrane Vesicles Provide Broad-Spectrum Protection against Influenza Virus Infection via Recruitment and Activation of Macrophages

FimH, a TLR4 ligand, induces innate antiviral responses in the lung leading to protection against lethal influenza infection in mice

Transurethral instillation with fusion protein MrpH.FimH induces protective innate immune responses against uropathogenic Escherichia coli and Proteus mirabilis

Viral infection. Prevention and cure of rotavirus infection via TLR5/NLRC4-mediated production of IL-22 and IL-18

Sublingual flagellin protects against acute pneumococcal pneumonia in a TLR5-dependent and NLRC4-independent fashion

Pathogen recognition and innate immunity

Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer

Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration

In vivo effects of a synthetic 2-kilodalton macrophage-activating lipopeptide of Mycoplasma fermentans after pulmonary application

Induction of cytokines and chemokines in human monocytes by Mycoplasma fermentans-derived lipoprotein MALP-2

Immunostimulation by synthetic lipopeptide-based vaccine candidates: structure-activity relationships

Structure and specific activity of macrophage-stimulating lipopeptides from Mycoplasma hyorhinis

Reducing the impact of influenza-associated secondary pneumococcal infections

Development of N-Acetylated Dipalmitoyl-S-Glyceryl Cysteine Analogs as Efficient TLR2/TLR6 Agonists

TLR2 agonism reverses chemotherapy-induced neutropenia in Macaca fascicularis

Induction of cross-tolerance by lipopolysaccharide and highly purified lipoteichoic acid via different Toll-like receptors independent of paracrine mediators

Administration of endotoxin associated with lipopolysaccharide tolerance protects mice against fungal infection

Induction of endotoxin tolerance enhances bacterial clearance and survival in murine polymicrobial sepsis

Lipopolysaccharide clearance, bacterial clearance, and systemic inflammatory responses are regulated by cell type-specific functions of TLR4 during sepsis

Neutrophil recruitment and bacterial clearance correlated with LPS responsiveness in local gramnegative infection

Infectious Agents as Stimuli of Trained Innate Immunity

Bacterial endotoxin: molecular relationships of structure to activity and function

The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex

Roles for LPS-dependent interaction and relocation of TLR4 and TRAM in TRIFsignaling

The role of MyD88-and TRIF-dependent signaling in monophosphoryl lipid A-induced expansion and recruitment of innate immunocytes

Synthetic toll-like receptor 4 agonists stimulate innate resistance to infectious challenge

Monophosphoryl Lipid a Attenuates Multiorgan Dysfunction During Post-Burn Pseudomonas Aeruginosa Pneumonia in Sheep

MPLA inhibits release of cytotoxic mediators from human neutrophils while preserving efficient bacterial killing

Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents

AS04, an aluminum salt-and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity

From discovery to licensure, the Adjuvant System story

High affinity retinoic acid receptor antagonists: analogs of AGN 193109

Administration of a synthetic TLR4 agonist protects mice from pneumonic tularemia

CD14-independent responses induced by a synthetic lipid A mimetic

Outer membrane vesicles harboring modified lipid A moiety augment the efficacy of an influenza vaccine exhibiting reduced endotoxicity in a mouse model

TLR4/MD-2 activation by a synthetic agonist with no similarity to LPS

Discovery and Structure-Activity Relationships of the Neoseptins: A New Class of Toll-like Receptor-4 (TLR4) Agonists

Bacterial flagellin-a potent immunomodulatory agent

Mucosal administration of flagellin protects mice from Streptococcus pneumoniae lung infection

Bacterial flagellin stimulates Toll-like receptor 5-dependent defense against vancomycin-resistant Enterococcus infection

A Toll-Like Receptor 5 Agonist Improves the Efficacy of Antibiotics in Treatment of Primary and Influenza Virus-Associated Pneumococcal Mouse Infections

TLR3 is essential for the induction of protective immunity against Punta Toro Virus infection by the double-stranded RNA (dsRNA), poly(I:C12U), but not Poly(I:C): differential recognition of synthetic dsRNA molecules

Effect of pretreatment with toll-like receptor agonists in a mouse model of herpes simplex virus type 1 encephalitis

Prophylactic and therapeutic intranasal administration with an immunomodulator, Hiltonol ((R)) (Poly IC:LC), in a lethal SARS-CoV-infected BALB/c mouse model

Pre-treatment with the viral Toll-like receptor 3 agonist poly(I:C) modulates innate immunity and protects neutropenic mice infected intracerebrally with Escherichia coli

Immunobiotic Lactobacillus rhamnosus improves resistance of infant mice against respiratory syncytial virus infection

Nasally administered Lactobacillus rhamnosus strains differentially modulate respiratory antiviral immune responses and induce protection against respiratory syncytial virus infection

Nasal priming with immunobiotic Lactobacillus rhamnosus modulates inflammation-coagulation interactions and reduces influenza virusassociated pulmonary damage

Peptidoglycan from Immunobiotic Lactobacillus rhamnosus Improves Resistance of Infant Mice to Respiratory Syncytial Viral Infection and Secondary Pneumococcal Pneumonia

Innate immune protection against infectious diseases by pulmonary administration of a phospholipid-conjugated TLR7 ligand

Intranasal and epicutaneous administration of Toll-like receptor 7 (TLR7) agonists provides protection against influenza A virus-induced morbidity in mice

A novel TLR7 agonist as adjuvant to stimulate high quality HBsAg-specific immune responses in an HBV mouse model

Immunizations with hepatitis B viral antigens and a TLR7/8 agonist adjuvant induce antigenspecific immune responses in HBV-transgenic mice

TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues

CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis

CpG oligodeoxynucleotides protect normal and SIV-infected macaques from Leishmania infection

A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection

CpG oligodeoxynucleotides stimulate protective innate immunity against pulmonary Klebsiella infection

CpG oligodeoxynucleotides enhance neonatal resistance to Listeria infection

CpG oligodeoxynucleotides protect newborn mice from a lethal challenge with the neurotropic Tacaribe arenavirus

CpG-DNA exerts antibacterial effects by protecting immune cells and producing bacteria-reactive antibodies

Intracellular toll-like receptors

Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks doublestranded RNA-mediated signaling

Toll-like receptor 3 promotes cross-priming to virus-infected cells

TLR3 agonists as immunotherapeutic agents

Foot-and-mouth disease virus inhibition induced in mice by synthetic double-stranded RNA (polyriboinosinic and polyribocytidylic acids)

Long-lasting antiviral innate immune priming in the Lophotrochozoan Pacific oyster

Length of dsRNA (poly I:C) drives distinct innate immune responses, depending on the cell type

Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice

Structural requirements of the rI n -rC n complex for induction of human interferon

The interferon inducer ampligen [poly(I)-poly(C12U)] markedly protects mice against coxsackie B3 virus-induced myocarditis

Results of a double-blind placebo-controlled study of the doublestranded RNA drug polyI:polyC12U in the treatment of HIV infection

Mismatched double-stranded RNA: polyI:polyC12U. Drugs RD

Intranasal immunization with H5N1 vaccine plus Poly I:Poly C12U, a Toll-like receptor agonist, protects mice against homologous and heterologous virus challenge

Intradermal immunisation using the TLR3-ligand Poly (I:C) as adjuvant induces mucosal antibody responses and protects against genital HSV-2 infection

A controlled clinical trial with a specifically configured RNA drug, poly(I).poly (C12U), in chronic fatigue syndrome

Changes in the 2-5A synthetase/RNase L antiviral pathway in a controlled clinical trial with poly(I)-poly(C12U) in chronic fatigue syndrome

Effect of a nuclease-resistant derivative of polyriboinosinic-polyribocytidylic acid complex on yellow fever in rhesus monkeys (Macaca mulatta)

Prophylactic and therapeutic efficacy of poly(I,C)-LC against Rift Valley fever virus infection in mice

Activation of toll-like receptor signaling pathway for protection against influenza virus infection

Liposomemediated immunotherapy against respiratory influenza virus infection using double-stranded RNA poly ICLC

Poly-ICLC, a TLR3 Agonist, Induces Transient Innate Immune Responses in Patients With Treated HIV-Infection: A Randomized Double-Blinded Placebo Controlled Trial

Vaccine adjuvant uses of poly-IC and derivatives

Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques

A TLR3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemic

An adjuvant for the induction of potent, protective humoral responses to an H5N1 influenza virus vaccine with antigen-sparing effect in mice

Characterization of an influenza A H5N2 reassortant as a candidate for liveattenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential

New strategies for the development of H5N1 subtype influenza vaccines: progress and challenges

PIKA as an adjuvant enhances specific humoral and cellular immune responses following the vaccination of mice with HBsAg plus PIKA

Ineffectiveness of rabies vaccination alone for post-exposure protection against rabies infection in animal models

A phase II randomized study to determine the safety and immunogenicity of the novel PIKA rabies vaccine containing the PIKA adjuvant using an accelerated regimen

The Role of Alveolar Macrophages in the Improved Protection against Respiratory Syncytial Virus and Pneumococcal Superinfection Induced by the Peptidoglycan of Lactobacillus rhamnosus CRL1505

Are the immunomodulatory properties of Lactobacillus rhamnosus CRL1505 peptidoglycan common for all Lactobacilli during respiratory infection in malnourished mice

Imiquimod applied topically: a novel immune response modifier and new class of drug

Novel Lipidated Imidazoquinoline TLR7/8 Adjuvants Elicit Influenza-Specific Th1 Immune Responses and Protect Against Heterologous H3N2 Influenza Challenge in Mice

UNC93B1 delivers nucleotide-sensing toll-like receptors to endolysosomes

The Chaperone UNC93B1 Regulates Toll-like Receptor Stability Independently of

TLR9 signals after translocating from the ER to CpG DNA in the lysosome

IRF-7 is the master regulator of type-I interferon-dependent immune responses

Bifurcation of Toll-like receptor 9 signaling by adaptor protein 3

Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria

Induction of innate immunity against herpes simplex virus type 2 infection via local delivery of Toll-like receptor ligands correlates with beta interferon production

A two-dose hepatitis B vaccine for adults (Heplisav-B)

186. van 't Wout JW, Poell R, van Furth R. The role of BCG/PPD-activated macrophages in resistance against systemic candidiasis in mice

Routine vaccinations and child survival: follow up study in

Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes

Long-lasting effects of BCG vaccination on both heterologous Th1/Th17 responses and innate trained immunity

Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guerin: involvement of toll-like receptors

The Complexity of Fungal beta-Glucan in Health and Disease: Effects on the Mononuclear Phagocyte System

Immunotherapeutic modification of Escherichia coli-induced experimental peritonitis and bacteremia by glucan

Protective effect of glucan against systemic Staphylococcus aureus septicemia in normal and leukemic mice

Glucan supplementation enhances the immune response against an influenza challenge in mice

Enhanced clearance of a multiple antibiotic resistant Staphylococcus aureus in rats treated with PGG-glucan is associated with increased leukocyte counts and increased neutrophil oxidative burst activity

Glucan phosphate treatment attenuates burn-induced inflammation and improves resistance to Pseudomonas aeruginosa burn wound infection

Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2

Dectin-1 mediates the biological effects of beta-glucans

Cutting edge: New chimeric NOD2/TLR2 adjuvant drastically increases vaccine immunogenicity

Signaling via pattern recognition receptors NOD2 and TLR2 contributes to immunomodulatory control of lethal pneumovirus infection

Innate immune memory through TLR2 and NOD2 contributes to the control of Leptospira interrogans infection

Synergistic effect of dual targeting vaccine adjuvant with aminated beta-glucan and CpG-oligodeoxynucleotides for both humoral and cellular immune responses

Immunomodulation by a low-virulence, agerminative variant of Candida albicans. Further evidence for macrophage activation as one of the effector mechanisms of nonspecific anti-infectious protection

Herpesvirus latency confers symbiotic protection from bacterial infection

gamma-Herpesvirus-induced protection against bacterial infection is transient

Adaptive immune features of natural killer cells

Targeting Toll-like receptors: emerging therapeutics?

The potential use of Toll-like receptor (TLR) agonists and antagonists as prophylactic and/or therapeutic agents

Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists

Therapeutic targeting of pattern-recognition receptors

Toll-like receptor 4 antagonist (E5564) prevents the chronic airway response to inhaled lipopolysaccharide

Inhibition of corneal inflammation by the TLR4 antagonist Eritoran tetrasodium (E5564)

Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia

Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial

A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis

Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines

A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial

Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial

Inhibition of Bruton tyrosine kinase in patients with severe COVID-19

GTS-21 inhibits pro-inflammatory cytokine release independent of the Toll-like receptor stimulated via a transcriptional mechanism involving JAK2 activation

Metabolic reprogramming in macrophages and dendritic cells in innate immunity

mTOR-and HIF-1alpha-mediated aerobic glycolysis as metabolic basis for trained immunity

Defining trained immunity and its role in health and disease

Regulation of leukocyte function by citric acid cycle intermediates

Krebs Cycle Reimagined: The Emerging Roles of Succinate and Itaconate as Signal Transducers

Toll-like Receptor Signaling Rewires Macrophage Metabolism and Promotes Histone Acetylation via ATP-Citrate Lyase

The sedoheptulose kinase CARKL directs macrophage polarization through control of glucose metabolism

Succinate is an inflammatory signal that induces IL-1beta through HIF-1alpha

HIF-1alpha is essential for myeloid cell-mediated inflammation

Metabolic Instruction of Immunity

Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization

Immune-responsive gene 1 protein links metabolism to immunity by catalyzing itaconic acid production

Itaconic Acid: The Surprising Role of an Industrial Compound as a Mammalian Antimicrobial Metabolite

IFNs Modify the Proteome of Legionella-Containing Vacuoles and Restrict Infection Via IRG1-Derived Itaconic Acid

Bacterial itaconate degradation promotes pathogenicity

Itaconate is an effector of a Rab GTPase cell-autonomous host defense pathway against Salmonella

Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1

The emerging role of Nrf2 in mitochondrial function

Comparative evaluation of itaconate and its derivatives reveals divergent inflammasome and type I interferon regulation in macrophages

The Itaconate Pathway Is a Central Regulatory Node Linking Innate Immune Tolerance and Trained Immunity

Itaconate Links Inhibition of Succinate Dehydrogenase with Macrophage Metabolic Remodeling and Regulation of Inflammation

TLR signalling augments macrophage bactericidal activity through mitochondrial ROS

Epigenetics and Trained Immunity

Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity

Glutaminolysis and Fumarate Accumulation Integrate Immunometabolic and Epigenetic Programs in Trained Immunity

alpha-ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming

Lysine succinylation and lysine malonylation in histones

Metabolic regulation of gene expression by histone lactylation

Trained immunity or tolerance: opposing functional programs induced in human monocytes after engagement of various pattern recognition receptors

Sepsis-induced immune dysfunction: can immune therapies reduce mortality?

Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach

Clinical aspects: from systemic inflammation to 'immunoparalysis

The Role of Toll-Like Receptors in Autoimmune Diseases through Failure of the Self-Recognition Mechanism

Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma

Oncogenically active MYD88 mutations in human lymphoma

Frequent inactivation of A20 in B-cell lymphomas

Mechanisms of Trained Innate Immunity in oxLDL Primed Human Coronary Smooth Muscle Cells

Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer

Preparation and evaluation of the adjuvant effect of curdlan sulfate in improving the efficacy of dendritic cellbased vaccine for antitumor immunotherapy

Attenuated expression of A20 markedly increases the efficacy of doublestranded RNA-activated dendritic cells as an anti-cancer vaccine

Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer

Toll-like receptor 4 signaling confers cardiac protection against ischemic injury via inducible nitric oxide synthase-and soluble guanylate cyclase-dependent mechanisms

Pre-conditioning with synthetic CpG-oligonucleotides attenuates myocardial ischemia/reperfusion injury via IL-10 up-regulation

Monophosphoryl Lipid-A: A Promising Tool for Alzheimer's Disease Toll

Toll-like receptor 4 stimulation with the detoxified ligand monophosphoryl lipid A improves Alzheimer's disease-related pathology

Trained Immunity Carried by Nonimmune Cells

Probiotic Modulation of Innate Cell Pathogen Sensing and Signaling Events

BCG-induced trained immunity: can it offer protection against COVID-19?

Could the Induction of Trained Immunity by beta-Glucan Serve as a Defense Against COVID-19? Front Immunol

Activation of TLR7 and Innate Immunity as an Efficient Method Against COVID-19 Pandemic: Imiquimod as a Potential Therapy

Recent clinical trends in Toll-like receptor targeting therapeutics

Trained Immunity-Based Vaccines: A New Paradigm for the Development of Broad-Spectrum Anti-infectious Formulations

Effects of 24-week Toll-like receptor 9 agonist treatment in HIV type 1+ individuals

AO is supported by 5T32AI38932-02, NP is supported by 5T32GM108554-05, Shock Society Faculty Research Award, and Vanderbilt Faculty Research Scholar Award, AH by K08 GM123345, and JB by R01 GM121711.

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.Copyright © 2021 Owen, Fults, Patil, Hernandez and Bohannon. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Angiotensin-converting-enzyme 2 AGP Aminoalkyl glucosamine 4-phosphate AP-